Lilly Asia Ventures

elsewhere's corpus doesn't carry a standalone profile of Lilly Asia Ventures (LAV) — its founding background and fund specifics aren't covered here. What the material does show is a consistently active healthcare investor across China's biotech and medical-device scene: it co-led ProfoundBio's oversubscribed $55 million Series A with LYFE Capital in 2021 , co-led Sirius Pharma's 300-million-yuan-plus Series B in 2025 , and has been a repeat backer of Pulnovo Medical — participating in its 2022 round , co-leading its nearly $100 million Series C with Qiming Venture Partners in 2025 , and following on in its $100 million Series D led by Medtronic in April 2026 . It also co-led Shize Biotech's early rounds alongside Qiming and continued adding to positions in Cornerstone Robotics and Syneron Bio's $150 million Series B in March 2026 — a pattern of leading early and staying in through later rounds. One naming caution: LAV is an investment fund, distinct from Eli Lilly the pharmaceutical company, which surfaces in this corpus separately through R&D licensing deals with Chinese biotechs like Insilico Medicine and Abbisko .